Stay updated on TMB & Neoantigen Relationship in Melanoma & Bladder Cancer Clinical Trial
Sign up to get notified when there's something new on the TMB & Neoantigen Relationship in Melanoma & Bladder Cancer Clinical Trial page.

Latest updates to the TMB & Neoantigen Relationship in Melanoma & Bladder Cancer Clinical Trial page
- Check3 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2; the 'Back to Top' element was removed.SummaryDifference0.2%
- Check10 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1.SummaryDifference0.2%
- Check17 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, as well as various new categories related to proteins and antibodies. Notably, previous references to certain diseases and antineoplastic agents have been removed.SummaryDifference5%
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check38 days agoChange DetectedThe web page has been updated to version v2.16.11, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.8%
- Check52 days agoChange DetectedThe webpage has been updated with new clinical results regarding bladder cancer treatments, including confirmed objective response rates for both nivolumab monotherapy and the combination therapy with ipilimumab. Additionally, specific reporting dates for results have been added.SummaryDifference9%
Stay in the know with updates to TMB & Neoantigen Relationship in Melanoma & Bladder Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TMB & Neoantigen Relationship in Melanoma & Bladder Cancer Clinical Trial page.